Cathie's Ark LogoCathie's Ark
BEGIN TYPING TO SEARCH BY TICKER
Fate Therapeutics Inc Logo

ARKK Holdings of Fate Therapeutics (FATE) - Updated Daily

Date
Direction
Shares
Fund Weight
Fund
August 8, 2022
SELL307.711k0.1033%ARKK
December 27, 2021
SELL13.150k0.0048%ARKK
September 8, 2021
BUY74.729k0.02%ARKK
September 7, 2021
BUY48.314k0.02%ARKK
September 3, 2021
BUY162.959k0.05%ARKK

Key Statistics

DateAugust 03, 2022Revenue
Expected$12.88m
Actual$18.55m
EPS
Expected-$0.83
Actual-$0.79
🕵🏼Found In🏷Last Price
ARKKARKG$32.84
⚖️Weighting🧢Market Cap
1.78%$3.19b
🏋🏿‍♂️Weight Rank In ARKK🧮Price to Sales
2046.67
🏋️‍♀️Weight Rank Across All Funds🌏Country
17🇺🇸United States
💳ARK Estimated Cost Average🎫ARK Ownership Percent
$83.586.68%
Description
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company's immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs). The Company's immuno-regulatory product candidates include ProTmune™, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease. Fate Therapeutics is headquartered in San Diego, CA.
Website
www.fatetherapeutics.com

Research Notes and Commentary for FATE

January 29, 2021

Ark Trades and Storylines

Trading Floor
Reported excellent Phase 1 clinical trial results for it's experimental CAR-NK therapy on...